MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SMTI stock logo

SMTI

Sanara MedTech Inc.

$17.24
-0.01
 (-0.06%)
Exchange:  NASDAQ
Market Cap:  158.04M
Shares Outstanding:  691166
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Instruments & Supplies
   
CEO:  Seth D. Yon
Full Time Employees:  141
Address: 
1200 Summit Avenue
Fort Worth
TX
76102
US
Website:  https://sanaramedtech.com
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako’s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako’s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako’s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/14 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue64,989.84186,672.425103,117.982
Gross Profit57,137.15578,532.52492,935.140
EBITDA-289.097-1,860.27911,807.531
Operating Income-4,215.153-6,715.4749,145.658
Net Income-4,303.197-9,664.547-37,562.606

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets73,871.14988,091.99272,944.071
Total Liabilities29,283.13249,180.03067,014.295
Total Stockholders Equity44,832.27739,403.5735,929.776
Total Debt11,792.1101,595.73848,192.869
Cash and Cash Equivalents5,147.21615,878.29516,578.857

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-3,245.556-23.7846,786.629
Capital Expenditure-265.246-205.848-4,625.650
Free Cash Flow-3,510.802-229.6322,160.979
Net Income-4,303.197-9,911.898-27,656.149
Net Change in Cash-3,811.77910,731.079-10,030.517

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2027Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)133,400Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)133,400Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)133,400Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)60,681.148Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)60,681.148Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)60,681.148Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)9,226.641Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)9,226.641Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)9,226.641Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)125,089.142Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)125,089.142Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)125,089.142Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.070Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.070Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.070Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
86.672M  ?P/S
 (TTM)
: 
1.53
?Net Income
 (TTM)
: 
-9664547  ?P/E
 (TTM)
: 
-3.96
?Enterprise Value
 (TTM)
: 
189.654M  ?EV/FCF
 (TTM)
: 
87.76
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.79  ?ROIC
 (TTM)
: 
0.17
?Net Debt
 (TTM)
: 
16.407M  ?Debt/Equity
 (TTM)
: 
8.13
?P/B
 (TTM)
: 
25.07  ?Current Ratio
 (TTM)
: 
1.8

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
107.75Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SMTI Intrinsic Value

Common questions about SMTI valuation

Is SMTI (SMTI) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for SMTI (SMTI) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is SMTI a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SMTI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is SMTI’s P/E ratio?

You can see SMTI’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for SMTI?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is SMTI a good long-term investment?

Whether SMTI fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

SMTI

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

-0.06
MARKETSnap

Trading Metrics:

Open:    Previous Close: 
Day Low:    Day High: 
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Sanara MedTech Inc. (SMTI) Q4 Earnings Miss Estimates
Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE® Advanced Surgical Solution
Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE® Advanced Surgical Solution
Sanara MedTech (SMTI) Upgraded to Strong Buy: Here's What You Should Know
Sanara MedTech (NASDAQ:SMTI) Stock Price Up 2%  – Here’s Why
Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
Sanara MedTech: Too Cheap And Better Positioned After Earlier Strategic Missteps

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read